Clinical Trial Update: A Dose Escalation Study of the Combination of Lenalidomide (Revlimid®), Dexamethasone and Cyclophosphamide in Patients Refractory or Relapsing From Stable Disease With Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 dose-escalation study evaluating a triplet of lenalidomide, dexamethasone, and cyclophosphamide in patients with relapsed or refractory multiple myelo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• DEXAMETHASONE (Dexamethasone)
• Revlimid (lenalidomide)

Snippet

Sponsor: King's College Hospital NHS Trust | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED